TICKERNERD
Menu
RLMDRLMDHealthcare · Biotechnology

RLMD Stock Forecast: Relmada Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$4.44
−1.77% on the day

The 5 Wall Street analysts covering Relmada Therapeutics, Inc. hold a median 12-month price target of $12 — +170.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$482.1M
Ticker Nerd rank
65 / 100
Median analyst target
$12
Analysts covering
5
Revenue$0.0
Operating income−$15.0M
Net income−$12.9M
Free cash flow−$9.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.2%
1M
−7.5%
YTD
−8.1%
1Y
+179.2%
From 52W high
−43.5%
From 52W low
+194.0%
$1.51
$7.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RLMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Relmada Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Revisions
76
Quality
61
Value
60
Growth
56
Size
54
Accruals
44
Volatility
38
Issuance
27

Momentum (83): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RLMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26RLMDHigh $19Median $12Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $9Median $12High $19

The green dot is the last close — the median target sits +170.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 June 2026HC Wainwright & Co.InitiatesBuy$12
24 Mar 2026Piper SandlerInitiatesOverweight—
20 Mar 2026MizuhoMaintainsOutperform—
2 Mar 2026LUCID CAPITAL MARKETSInitiatesBuy—
23 Jan 2026Leerink PartnersUpgradeOutperform—
22 Dec 2025JefferiesInitiatesBuy—
19 Nov 2025MizuhoUpgradeOutperform—
5 Dec 2024MizuhoDowngradeNeutral—
4 Dec 2024Leerink PartnersDowngradeMarket Perform—
17 Sept 2024JefferiesUpgradeBuy$3.50 → $13
5 June 2024Goldman SachsDowngradeSell—
15 June 2023MizuhoReiteratesBuy—
23 Jan 2023SVB LeerinkMaintainsOutperform—
14 Oct 2022Goldman SachsDowngradeNeutral—
14 Oct 2022GuggenheimDowngradeNeutral—
13 Oct 2022OppenheimerDowngradePerform—
23 Sept 2022Goldman SachsMaintainsBuy—
6 Sept 2022GuggenheimMaintainsBuy—
9 May 2022OppenheimerMaintainsOutperform—
24 Mar 2022Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RLMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Relmada Therapeutics, Inc. returned +179.2% against +17.5% for the S&P 500, dividends included.

RLMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26RLMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RLMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Relmada Therapeutics, Inc. (RLMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
4.7×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−25.6%

Higher than 29% of US stocks

Return on assets
−14.4%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Relmada Therapeutics, Inc. (RLMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Relmada Therapeutics, Inc. has a market value of $482.1M and an enterprise value of −$64.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$61.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M.

  • Shares outstanding: 106.7M.

  • Trailing P/E: −3.1×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Relmada Therapeutics, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

RLMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLMDRelmada Therapeutics, Inc.$482.1M
65
SPRYARS Pharmaceuticals, Inc.$470.5M
13
PRTAProthena Corp. Plc$480.7M
98
CAPRCapricor Therapeutics, Inc.$481.4M
9
EIKNEikon Therapeutics, Inc.$483.7M
1
PBYIPuma Biotechnology, Inc.$464.1M
92
VOGXVogenx, Inc.$485.9M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Relmada Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RLMD news & analysis

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Zacks Investment Research · 14 Sept 2026positive

Zacks Investment Research named RLMD among five small drug stocks (alongside INDV, IRWD, LRMR and CRDL) poised to benefit from an improving biotech sentiment, citing catalysts and differentiated pipelines as potential sources of upside.

Why it matters — The mention suggests RLMD is seen as having differentiated pipeline catalysts that could gain traction as broader biotech sentiment improves.

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Relmada Therapeutics announced that its senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference, held in Boston from September 8-10, 2026. The announcement was made on September 1, 2026.

Why it matters — The company's participation in a major healthcare investor conference provides an opportunity for increased visibility and engagement with the investment community.

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Zacks Investment Research · 31 Aug 2026positive

Relmada Therapeutics (RLMD) has become technically oversold, which implies exhaustion of heavy selling pressure, according to Zacks Investment Research. This condition, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Why it matters — RLMD watchers would care because an oversold technical condition paired with upward analyst estimate revisions points to a possible short-term turnaround after the recent decline.

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

Zacks Investment Research · 25 Aug 2026positive

Zacks reports that Relmada Therapeutics (RLMD) has shown signs of finding support after recent losses, as indicated by a hammer chart pattern, and that Wall Street analysts are in strong agreement in revising earnings estimates higher, which the article suggests enhances the stock's potential for a near-term turnaround.

Why it matters — RLMD watchers would care because the article highlights a technical support signal and upward analyst estimate revisions that could point to a potential turnaround for the stock.

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Zacks Investment Research · 11 Aug 2026positive

The article notes that Relmada Therapeutics (RLMD) shares have fallen 29.6% over four weeks and are now technically in oversold territory, suggesting the selling pressure may have run its course.

Why it matters — RLMD watchers would care because the combination of an oversold technical condition and broad analyst agreement in raising earnings estimates could signal a potential trend reversal for the stock.

FAQ

Frequently asked questions about RLMD stock

What is the RLMD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Relmada Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $9 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RLMD stock a buy right now?

Of the 5 analysts covering Relmada Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relmada Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLMD?

As at 12 Sept 2026, Relmada Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will RLMD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +170.3% from the last close, and Ticker Nerd's factor model ranks Relmada Therapeutics, Inc. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RLMD stock forecast for 2030?

No analyst covering Relmada Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $19 over the next 12 months.

How has RLMD stock performed over the past year?

Relmada Therapeutics, Inc. returned +179.2% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Relmada Therapeutics, Inc. do?

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders.

What is the latest news on RLMD?

The most recent item we track (Zacks Investment Research, 14 Sept 2026): "5 Small Drug Stocks Poised to Benefit From a Biotech Recovery". Zacks Investment Research named RLMD among five small drug stocks (alongside INDV, IRWD, LRMR and CRDL) poised to benefit from an improving biotech sentiment, citing catalysts and differentiated pipelines as potential sources of upside.

Company

About Relmada Therapeutics, Inc.

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions. The company also advances esmethadone, a novel NMDA receptor antagonist being evaluated for central nervous system indications such as major depressive disorder and other related disorders. Relmada Therapeutics Inc. operates as a research-driven drug developer, using targeted clinical programs to explore new treatment options across cancer, psychiatric, and neurological care. Headquartered in Coral Gables, Florida, the company remains focused on late-stage development of proprietary therapies intended to expand treatment possibilities in specialized disease areas.

CEO Dr. Sergio Traversa M.B.A., Pharm.D. · 17 employees · United States · https://www.relmada.com